Aliases & Classifications for Malignant Glioma

MalaCards integrated aliases for Malignant Glioma:

Name: Malignant Glioma 38 55 73

Classifications:



External Ids:

UMLS 73 C0555198

Summaries for Malignant Glioma

MalaCards based summary : Malignant Glioma is related to glioma and glioblastoma. An important gene associated with Malignant Glioma is FOXD3-AS1 (FOXD3 Antisense RNA 1
Systemic analysis of the patient specimens and clinical data showed that FOXD3-AS1 was markedly up-regulated in high-grade glioma tissues (WHO grade III-IV) compared with that in low-grade glioma (WHO grade I-II) and normal brain tissues (both P<0.01), and patients with low FOXD3-AS1 expression had grater survival probability.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone.

Related Diseases for Malignant Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Malignant Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Related Disease Score Top Affiliating Genes
1 glioma 29.1 CDKN2B-AS1 CRNDE CYTOR GAS5 H19 HOTTIP
2 glioblastoma 28.8 CYTOR GAS5 H19 LINC00963 MALAT1 MEG3
3 melanoma 27.0 CDKN2B-AS1 GAS5 H19 HOXA-AS2 LINC-ROR MALAT1
4 astrocytoma 11.3
5 mismatch repair cancer syndrome 10.9
6 meningioma, familial 10.9
7 malignant ependymoma 10.9
8 triple-receptor negative breast cancer 10.4 LINC-ROR MALAT1
9 gastric cardia adenocarcinoma 10.4 H19 MEG3
10 endotheliitis 10.3
11 pancreatic ductal adenocarcinoma 10.3 H19 HOTTIP MALAT1
12 coronary artery anomaly 10.2 CDKN2B-AS1 GAS5 H19 HOTTIP
13 hypoxia 10.1
14 herpes simplex 10.1
15 vulva squamous cell carcinoma 10.0 MALAT1 MEG3
16 cerebritis 10.0
17 pituitary adenoma 9.9 H19 MALAT1 MEG3
18 ovarian epithelial cancer 9.9 H19 MALAT1 MEG3
19 glioma susceptibility 1 9.9
20 glioblastoma multiforme 9.9
21 wilms tumor 1 9.8
22 wilms tumor 5 9.8
23 wilms tumor 6 9.8
24 brain cancer 9.8
25 grade iii astrocytoma 9.8
26 neuronitis 9.8
27 type i 9.8
28 ewing's family of tumors 9.8
29 osteoarthritis 9.8 GAS5 H19 MEG3
30 oral squamous cell carcinoma 9.8 H19 MALAT1 MEG3
31 medulloblastoma 9.8
32 aging 9.8
33 arteriovenous malformation 9.8
34 prostatitis 9.8
35 cholera 9.8
36 lymphopenia 9.8
37 meningitis 9.8
38 encephalitis 9.8
39 cytomegalovirus infection 9.8
40 kidney cancer 9.7 GAS5 H19 MALAT1 MEG3
41 tongue squamous cell carcinoma 9.7 CYTOR HOTTIP MALAT1 MEG3
42 bladder urothelial carcinoma 9.6 CRNDE GAS5 MALAT1 MEG3
43 clear cell renal cell carcinoma 9.6 CYTOR MALAT1 MEG3
44 myeloma, multiple 9.6 GAS5 H19 MALAT1 MEG3
45 immunodeficiency-centromeric instability-facial anomalies syndrome 1 9.6
46 pulmonary arteriovenous fistulas 9.6
47 meningioma, radiation-induced 9.6
48 arteriovenous fistula 9.6
49 hepatitis 9.6
50 hepatitis b 9.6

Graphical network of the top 20 diseases related to Malignant Glioma:



Diseases related to Malignant Glioma

Symptoms & Phenotypes for Malignant Glioma

Drugs & Therapeutics for Malignant Glioma

Drugs for Malignant Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 414)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Dabrafenib Approved, Investigational Phase 4,Phase 2,Phase 1 1195765-45-7 44462760 44516822
4
Trametinib Approved Phase 4,Phase 2 871700-17-3 11707110
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Protein Kinase Inhibitors Phase 4,Phase 1,Phase 2,Not Applicable
10
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
11
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
12
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
13
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
14
Ifosfamide Approved Phase 3 3778-73-2 3690
15
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
16
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
17
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
18
Procarbazine Approved, Investigational Phase 3,Phase 2,Not Applicable 671-16-9 4915
19
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
20
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
21
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
22
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
23
Levoleucovorin Approved, Investigational Phase 3,Phase 1 68538-85-2
24
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
25
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
26
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
27
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
28
Modafinil Approved, Investigational Phase 3,Phase 2 68693-11-8 4236
29
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
30
Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
31
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
32
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
33
Dalteparin Approved Phase 3,Not Applicable 9005-49-6
34
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
35
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
36
Armodafinil Approved, Investigational Phase 3,Phase 2 112111-43-0
37
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
38
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
39
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
41
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
43
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
44
Vitamin C Approved, Nutraceutical Phase 3,Phase 1,Phase 2 50-81-7 5785 54670067
45
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
46 tannic acid Approved, Nutraceutical Phase 3,Phase 2
47
Isophosphamide mustard Phase 3 0
48 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
49 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
50 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 668)
# Name Status NCT ID Phase Drugs
1 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
2 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
3 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
4 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
5 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
6 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
7 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
8 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
9 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
10 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
11 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
12 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
13 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
14 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
15 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
16 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
17 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
18 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
19 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
20 Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Recruiting NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
21 3D Ultra Sound for Resection of Brain Tumors Recruiting NCT02150564 Phase 3
22 Fluorescence-guided Surgery for Low- and High-grade Gliomas Recruiting NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
23 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
24 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
25 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
26 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
27 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Not yet recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
28 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
29 XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
30 Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT01144988 Phase 2 Bevacizumab / Irinotecan
31 Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas Unknown status NCT01670890 Phase 2 TMZ;TMZ plus CDDP
32 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
33 Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas Unknown status NCT01140568 Phase 2 nilotinib
34 Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma Unknown status NCT00283543 Phase 2 Gliadel Wafer;Temozolomide
35 Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma Unknown status NCT01235845 Phase 1, Phase 2
36 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
37 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
38 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
39 A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660283 Phase 2 Temozolomide
40 A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660621 Phase 2 Temozolomide and Bevacizumab
41 Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma Unknown status NCT02481960 Phase 1, Phase 2
42 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
43 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
44 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
45 Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) Unknown status NCT02772094 Phase 2
46 Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00906516 Phase 2 Neuradiab in combination with Bevacizumab (Avastin)
47 Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT02139579 Phase 2 Bevacizumab
48 CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients Completed NCT02575261 Phase 1, Phase 2
49 A Phase II Study to Treat Advanced Malignant Glioma Completed NCT00427440 Phase 2 AMG 102 at 20 mg/kg;AMG 102 at 10 mg/kg
50 Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas Completed NCT00766753 Phase 1, Phase 2

Search NIH Clinical Center for Malignant Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Malignant Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Malignant Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to Malignant Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Genetic Tests for Malignant Glioma

Anatomical Context for Malignant Glioma

MalaCards organs/tissues related to Malignant Glioma:

41
Brain, T Cells, Bone, Endothelial, Bone Marrow, Liver, Testes

Publications for Malignant Glioma

Articles related to Malignant Glioma:

(show top 50) (show all 1244)
# Title Authors Year
1
Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. ( 29441040 )
2018
2
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. ( 29666296 )
2018
3
Staged Image-guided Robotic Radiosurgery and Deferred Chemotherapy to Treat a Malignant Glioma During and After Pregnancy. ( 29632751 )
2018
4
Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. ( 29571074 )
2018
5
Sinomenine Induces G1-Phase Cell Cycle Arrest and Apoptosis in Malignant Glioma Cells Via Downregulation of Sirtuin 1 and Induction of p53 Acetylation. ( 29756546 )
2018
6
Hyperbaric oxygen inhibits production of CD3+ T cells in the thymus and facilitates malignant glioma cell growth. ( 29785863 )
2018
7
The long non-coding RNA <i>HOTAIR</i> is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. ( 29644006 )
2018
8
ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. ( 29017962 )
2018
9
Immunotherapies for malignant glioma. ( 29242608 )
2018
10
Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma. ( 29343959 )
2018
11
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. ( 29404979 )
2018
12
Combination therapy of intravenously injected microglia and radiotherapy prolongs survival in a rat model of spontaneous malignant glioma. ( 29928947 )
2018
13
Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma. ( 29689474 )
2018
14
5-ALA in the management of malignant glioma. ( 29737540 )
2018
15
Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats. ( 29658349 )
2018
16
Par-4-dependent p53 up-regulation plays a critical role in thymoquinone-induced cellular senescence in human malignant glioma cells. ( 29656006 )
2018
17
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells. ( 29208287 )
2018
18
Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis. ( 29310118 )
2018
19
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. ( 29712687 )
2018
20
B<i>m</i>K CT enhances the sensitivity of temozolomide-induced apoptosis of malignant glioma U251 cells<i>in vitro</i>through blocking the AKT signaling pathway. ( 29434848 )
2018
21
Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. ( 29391393 )
2018
22
Microfluidics in Malignant Glioma Research and Precision Medicine. ( 29780878 )
2018
23
&amp;quot;Simple Methods to Derive Primary Malignant Glioma Cell Lines and Assay of Cellular Damage for Preclinical Studies&amp;quot;. ( 29405781 )
2018
24
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. ( 29703821 )
2018
25
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. ( 29133513 )
2018
26
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma. ( 29780071 )
2018
27
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. ( 29432077 )
2018
28
Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. ( 29251333 )
2018
29
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line. ( 29747444 )
2018
30
LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma. ( 29723732 )
2018
31
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide: A Case Report. ( 29780148 )
2018
32
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( 29803991 )
2018
33
Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma. ( 28645200 )
2017
34
CCR7 Mediates TGF-I^1-Induced Human Malignant Glioma Invasion, Migration, and Epithelial-Mesenchymal Transition by Activating MMP2/9 Through the Nuclear Factor KappaB Signaling Pathway. ( 28817313 )
2017
35
Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma. ( 29271010 )
2017
36
Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma. ( 28912488 )
2017
37
Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models. ( 29290950 )
2017
38
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China. ( 28409559 )
2017
39
Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis. ( 28886531 )
2017
40
Apparent transverse relaxation (R2a89) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma. ( 29193849 )
2017
41
Precursor N-cadherin mediates glial cell line-derived neurotrophic factor-promoted human malignant glioma. ( 28212546 )
2017
42
Wavelength-specific lighted suction instrument for 5-aminolevulinic acid fluorescence-guided resection of deep-seated malignant glioma: technical note. ( 28665248 )
2017
43
Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway. ( 28401302 )
2017
44
Study of antioxidant effects on malignant glioma cells by constructing a tumor-microvascular structure on microchip. ( 28595721 )
2017
45
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. ( 28488122 )
2017
46
IKBKE regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the Hippo pathway. ( 28548934 )
2017
47
Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. ( 29119041 )
2017
48
CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. ( 28534507 )
2017
49
Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma. ( 28594449 )
2017
50
Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma. ( 28321704 )
2017

Variations for Malignant Glioma

Copy number variations for Malignant Glioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma

Expression for Malignant Glioma

Search GEO for disease gene expression data for Malignant Glioma.

Pathways for Malignant Glioma

Pathways related to Malignant Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 LINC-ROR MEG3

GO Terms for Malignant Glioma

Sources for Malignant Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....